CEO’s Insider Buy Signals SCYNEXIS’s Strong Orphan‑Drug UpsideInsider buying signals confidence in SCYNEXIS’s orphan‑drug strategy, highlighting CEO‑led equity stake, Phase 2 milestones, and high‑pricing potential.SCYNEXIS Inc Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated DirectorDealingsBot 02/04/2026, 14:17 4 minutes to read
